Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Eur J Nucl Med Mol Imaging · 2017 · PMC5281649 · PMID 27633250

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the phase 2 trial, sembragiline at 1 and 5 mg daily failed on the primary efficacy outcome on cognition (Alzheimer’s Disease Assessment Scale–cognitive subscale (ADAS-Cog11) but showed a trend toward an effect on functioning and potential for an effect on neuropsychiatric symptoms compared with placebo.

also in 53,322 other papers

a slight trendno p-value reported

When corrected for age, a slight trend for higher λ k 3 in patients with AD was observed.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.